03:55 PM EDT, 07/28/2025 (MT Newswires) -- Health care stocks declined late Monday afternoon, with the NYSE Health Care Index decreasing 1% and the Health Care Select Sector SPDR Fund (XLV) down 0.8%.

The iShares Biotechnology ETF (IBB) slipped 0.8%.

In corporate news, Adaptimmune Therapeutics ( ADAP ) shares tumbled 71% after the firm said it has agreed to sell its cell therapy programs Tecelra, lete-cel, afami-cel, and uza-cel to US WorldMeds for $55 million in cash, with potential milestone payments of up to $30 million.

Revvity ( RVTY ) shares fell 9% after it posted a drop in Q2 adjusted earnings and updated its 2025 guidance.

Renovaro ( RENB ) shares rose 2% after the company reported multiple US patent allowances, including an application for unbiased drug discovery predictions.

Celcuity ( CELC ) shares surged 170% after the firm said a phase 3 trial of its drug gedatolisib plus fulvestrant, with and without palbociclib, showed a "statistically significant and clinically meaningful" improvement in progression-free survival among patients in a type of breast cancer.